Michael C. Irizarry

19.7k total citations · 7 hit papers
166 papers, 13.2k citations indexed

About

Michael C. Irizarry is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Michael C. Irizarry has authored 166 papers receiving a total of 13.2k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Physiology, 57 papers in Psychiatry and Mental health and 34 papers in Molecular Biology. Recurrent topics in Michael C. Irizarry's work include Alzheimer's disease research and treatments (94 papers), Dementia and Cognitive Impairment Research (50 papers) and Computational Drug Discovery Methods (21 papers). Michael C. Irizarry is often cited by papers focused on Alzheimer's disease research and treatments (94 papers), Dementia and Cognitive Impairment Research (50 papers) and Computational Drug Discovery Methods (21 papers). Michael C. Irizarry collaborates with scholars based in United States, United Kingdom and Japan. Michael C. Irizarry's co-authors include Bradley T. Hyman, Hiroaki Fukumoto, John H. Growdon, Shobha Dhadda, Lynn D. Kramer, Michio Kanekiyo, Chad J. Swanson, Larisa Reyderman, Karen Hsiao and Kathy L. Newell and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Michael C. Irizarry

157 papers receiving 13.0k citations

Hit Papers

Lecanemab ... 1997 2026 2006 2016 2022 1999 2004 1997 2022 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lecanemab in Early Alzheimer’s Disease
    2022 2.7k citations Christopher H. van Dyck, Chad J. Swanson et al. New England Journal of Medicine profile →
  2. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice
    1999 773 citations Michael C. Irizarry et al. profile →
  3. Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain
    2004 531 citations John H. Growdon, Bradley T. Hyman et al. profile →
  4. APPSW Transgenic Mice Develop Age-related Aβ Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1
    1997 526 citations Michael C. Irizarry, Bradley T. Hyman et al. profile →
  5. Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
    2022 185 citations Shobha Dhadda, Chad J. Swanson et al. profile →
  6. The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease
    2022 130 citations Reisa A. Sperling, Michael Donohue et al. Alzheimer s & Dementia profile →
  7. Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease
    2024 61 citations Christopher H. van Dyck, Reisa A. Sperling et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael C. Irizarry United States 56 8.4k 3.4k 3.0k 2.6k 2.2k 166 13.2k
Michael Mullan United States 64 7.9k 0.9× 5.5k 1.6× 2.2k 0.7× 2.1k 0.8× 3.8k 1.7× 319 15.3k
Teresa Gómez‐Isla United States 55 8.5k 1.0× 3.6k 1.1× 3.5k 1.2× 2.9k 1.1× 2.8k 1.3× 116 13.7k
Gerard D. Schellenberg United States 65 9.5k 1.1× 7.7k 2.3× 2.1k 0.7× 2.6k 1.0× 2.4k 1.1× 214 16.9k
Hugo Vanderstichele Belgium 57 10.8k 1.3× 4.6k 1.4× 6.6k 2.2× 1.5k 0.6× 2.5k 1.2× 156 14.8k
Lars Bertram Germany 48 6.1k 0.7× 5.3k 1.6× 1.7k 0.6× 2.0k 0.8× 1.5k 0.7× 172 13.0k
Dale Schenk United States 49 11.1k 1.3× 5.4k 1.6× 1.7k 0.6× 2.9k 1.1× 2.7k 1.2× 84 14.3k
Eugeen Vanmechelen Belgium 66 10.8k 1.3× 4.3k 1.3× 6.5k 2.2× 1.7k 0.7× 2.8k 1.3× 162 14.3k
Eric Siemers United States 45 7.2k 0.9× 2.6k 0.8× 4.5k 1.5× 1.7k 0.6× 1.7k 0.8× 167 12.0k
Christopher H. van Dyck United States 49 5.3k 0.6× 2.6k 0.8× 3.6k 1.2× 2.9k 1.1× 1.7k 0.8× 162 13.0k
Paul T. Francis United Kingdom 61 4.7k 0.6× 3.4k 1.0× 1.9k 0.7× 3.8k 1.5× 1.7k 0.8× 249 12.3k

Countries citing papers authored by Michael C. Irizarry

Since Specialization
Citations

This map shows the geographic impact of Michael C. Irizarry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael C. Irizarry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael C. Irizarry more than expected).

Fields of papers citing papers by Michael C. Irizarry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael C. Irizarry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael C. Irizarry. The network helps show where Michael C. Irizarry may publish in the future.

Co-authorship network of co-authors of Michael C. Irizarry

This figure shows the co-authorship network connecting the top 25 collaborators of Michael C. Irizarry. A scholar is included among the top collaborators of Michael C. Irizarry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael C. Irizarry. Michael C. Irizarry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Christopher, Sadao Katayama, Jae Hong Lee, et al.. (2025). Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease. The Journal of Prevention of Alzheimer s Disease. 12(5). 100160–100160. 9 indexed citations
2.
Devanarayan, Viswanath, Yuanqing Ye, Lü Tian, et al.. (2025). Predicted natural progression as an Alzheimer's prognostic covariate improves the precision of lecanemab efficacy assessments and clinical trial efficiency. Alzheimer s & Dementia. 21(3). e70045–e70045. 2 indexed citations
3.
Devanarayan, Viswanath, Michael Donohue, Reisa A. Sperling, et al.. (2025). Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease. Alzheimer s & Dementia. 21(9). e70702–e70702. 2 indexed citations
4.
Devanarayan, Viswanath, T. Doherty, Arnaud Charil, et al.. (2024). Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease. Alzheimer s & Dementia. 20(8). 5617–5628. 21 indexed citations
5.
Fox, Nick C., Arnaud Charil, Perminder S. Sachdev, et al.. (2024). "Paradoxical” Cerebral Volume Changes in Anti‐Amyloid Immunotherapy Trials. Alzheimer s & Dementia. 20(S6). 1 indexed citations
6.
Devanarayan, Viswanath, Daniel A. Llano, Yan Hu, et al.. (2024). Plasma pTau181 enhances the prediction of future clinical decline in amyloid‐positive mild cognitive impairment. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 16(3). e12621–e12621. 3 indexed citations
7.
Raman, Rema, Andy Liu, Oliver Langford, et al.. (2024). Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial. Alzheimer s & Dementia. 20(6). 3827–3838. 18 indexed citations
8.
Weninger, Stacie, Michael C. Irizarry, Adam Fleisher, et al.. (2024). Alzheimer's disease drug development in an evolving therapeutic landscape. Alzheimer s & Dementia Translational Research & Clinical Interventions. 10(4). e70015–e70015. 1 indexed citations
9.
Charil, Arnaud, Youfang Cao, Brian A. Willis, et al.. (2024). Lecanemab Slows Tau PET Accumulation. Alzheimer s & Dementia. 20(S6). 3 indexed citations
10.
Wildsmith, Kristin R., Perminder S. Sachdev, Kanta Horie, et al.. (2024). Lecanemab Slows Amyloid‐Induced Tau Pathology as Supported by CSF MTBR‐tau243 in Clarity AD. Alzheimer s & Dementia. 20(S8). 2 indexed citations
11.
Sperling, Reisa A., Shobha Dhadda, David Li, et al.. (2024). Is there Evidence for a Continued Benefit for Long‐Term Lecanemab Treatment? A Benefit/Risk Update from Long‐Term Efficacy, Safety and Biomarker Data. Alzheimer s & Dementia. 20(S6). 3 indexed citations
12.
Selkoe, Dennis J., Shobha Dhadda, Michael C. Irizarry, & Lynn D. Kramer. (2024). Does the Current Evidence for Lecanemab Mechanism Support a Rationale for Continued Lecanemab Dosing?. Alzheimer s & Dementia. 20(S6). 1 indexed citations
13.
Irizarry, Michael C.. (2023). Lecanemab: Amyloid Reduction and Evidence of Downstream Biomarker Modification. Alzheimer s & Dementia. 19(S15). 1 indexed citations
14.
Cohen, Sarah, Christopher H. van Dyck, Michelle Gee, et al.. (2023). Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease. The Journal of Prevention of Alzheimer s Disease. 10(4). 771–777. 50 indexed citations
15.
Dyck, Christopher H. van, Chad J. Swanson, Paul Aisen, et al.. (2022). Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine. 388(1). 9–21. 2741 indexed citations breakdown →
16.
Yaffe, Kristine, Michael Tocco, Ronald C. Petersen, et al.. (2012). The epidemiology of Alzheimer's disease: Laying the foundation for drug design, conduct, and analysis of clinical trials. Alzheimer s & Dementia. 8(3). 237–242. 19 indexed citations
17.
Serrano‐Pozo, Alberto, Gloria Lena Vega, Dieter Lütjohann, et al.. (2010). Effects of Simvastatin on Cholesterol Metabolism and Alzheimer Disease Biomarkers. Alzheimer Disease & Associated Disorders. 24(3). 220–226. 60 indexed citations
18.
19.
Arnim, Christine A. F. Von, Robert Spoelgen, Ithan D. Peltan, et al.. (2006). GGA1 Acts as a Spatial Switch Altering Amyloid Precursor Protein Trafficking and Processing. Journal of Neuroscience. 26(39). 9913–9922. 52 indexed citations
20.
Yoshimura, Shinichi, Tetsuyuki Teramoto, Michael J. Whalen, et al.. (2003). FGF-2 regulates neurogenesis and degeneration in the dentate gyrus after traumatic brain injury in mice. Journal of Clinical Investigation. 112(8). 1202–1210. 145 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Mullan Breakdown of academic impact, for papers by Teresa Gómez‐Isla Breakdown of academic impact, for papers by Gerard D. Schellenberg Breakdown of academic impact, for papers by Hugo Vanderstichele Breakdown of academic impact, for papers by Lars Bertram Breakdown of academic impact, for papers by Dale Schenk Breakdown of academic impact, for papers by Eugeen Vanmechelen Breakdown of academic impact, for papers by Eric Siemers Breakdown of academic impact, for papers by Christopher H. van Dyck Breakdown of academic impact, for papers by Paul T. Francis
Rankless by CCL
2026